Fayfman M, et al. - In non–critically ill patients with type 2 diabetes (T2D), researchers tested the safety and effectiveness of exenatide alone or in combination with basal insulin. In this multicenter, open-label, randomized trial, 150 patients with blood glucose levels between 140 and 400 mg/dL, treated at home with diet, oral agents, or insulin at a total daily dose < 0.5 units/kg, were randomized to exenatide alone (5 μg twice daily), exenatide plus basal insulin, or a basal-bolus insulin regimen. Among those in the basal plus exenatide, exenatide only, and basal-bolus groups, no differences in hypoglycemia < 54 mg/dL or length of stay were noted. More patients in the exenatide only and exenatide plus basal groups had nausea or vomiting vs those in the basal-bolus group, with three patients (6%) discontinued exenatide due to adverse events. According to findings, exenatide alone or in combination with basal insulin is safe and efficient for the management of hospitalized general medical and surgical patients with T2D.